Secondary amyloidosis medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
Line 69: | Line 69: | ||
*[[Mesalazine]] | *[[Mesalazine]] | ||
*[[Azathioprine]] | *[[Azathioprine]] | ||
*Methotrexate | *[[Methotrexate toxicity|Methotrexate]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
Biologic agents | Biologic agents | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Infliximab | *[[Infliximab]] | ||
*Adalimumab | *[[Adalimumab]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
Antibiotics | Antibiotics | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Metronidazole | *[[Metronidazole]] | ||
*Ciprofloxacin | *[[Ciprofloxacin]] | ||
*Azithromycin | *[[Azithromycin]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
Biologic agents | Biologic agents | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Infliximab | *[[Infliximab]] | ||
*Adalimumab | *[[Adalimumab]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
Surgery | Surgery | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
ileo-cecal resection and primary reconstruction | * ileo-cecal resection and primary reconstruction | ||
|- | |- | ||
| rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" | Immunodeficiency | | rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" | Immunodeficiency | ||
Line 103: | Line 103: | ||
Antibiotics | Antibiotics | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Cotrimoxazole | *[[Cotrimoxazole]] | ||
*Miconazole | *[[Miconazole]] | ||
|- | |- | ||
| rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" | Chronic infections | | rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" | Chronic infections | ||
Line 124: | Line 124: | ||
Antibiotics | Antibiotics | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Cotrimoxazole | *[[Cotrimoxazole]] | ||
*Miconazole | *[[Miconazole]] | ||
|- | |- | ||
| rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" | Neoplasia | | rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" | Neoplasia | ||
Line 135: | Line 135: | ||
Biologic agents (in Castleman disease) | Biologic agents (in Castleman disease) | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* Tocilizumab | *[[Tocilizumab]] | ||
|- | |- | ||
|} | |} |
Revision as of 13:30, 30 October 2019
Secondary amyloidosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Secondary amyloidosis medical therapy On the Web |
American Roentgen Ray Society Images of Secondary amyloidosis medical therapy |
Risk calculators and risk factors for Secondary amyloidosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Roukoz A. Karam, M.D.[2]
Overview
Medical or surgical treatment of the underlying chronic infection or inflammatory disease is recommended among all patients who develop AA amyloidosis.
Medical Therapy
- Medical or surgical treatment of the underlying chronic infection or inflammatory disease is recommended among all patients who develop AA amyloidosis.
- Aggressively treating the disease that is causing the excess amyloid protein can improve symptoms and slow down or halt the progression of the disease.
- Complications such as heart failure, renal failure, and other problems can sometimes be treated, when needed.
- Although the choice of therapy depends on the underlying cause of chronic inflammation, the aim is always to suppress production of SAA to within the normal range.
- Examples of treatments for the commonest disorders underlying AA amyloidosis, adapted from Rheumatic Diseases Clinics of North America:[1]
Underlying Condition | Treatment Options | Examples |
---|---|---|
Inflammatory arthritis | Conventional disease-modifying agents | |
Other immunosuppressant agents |
||
Biologic agents |
||
Periodic fevers | On-demand agents | |
Colchicine (for familial mediterranean fever) |
||
Biologic agents |
||
Inflammatory bowel disease | Conventional disease-modifying agents | |
Biologic agents |
||
Antibiotics |
||
Biologic agents |
||
Surgery |
| |
Immunodeficiency | Immunoglobulins |
|
Antibiotics |
||
Chronic infections | Antibiotics and surgery |
|
Physiotherapy (in case of bronchiectasis) |
| |
Immunodeficiency | Immunoglobulins |
|
Antibiotics |
||
Neoplasia | Chemotherapy and surgery |
Varies according to type of cancer |
Biologic agents (in Castleman disease) |
- Long-term inflammatory control can be accompanied by gradual regression of amyloid deposits and improvement in renal function.
- Currently a second clinical trial is in progress in order to evaluate a targeted inhibitor molecule, Kiacta, in the management of secondary amyloidosis.
- Novel therapies aimed at promoting clearance of existing amyloid deposits soon may be an effective treatment approach.
References
- ↑ Papa R, Lachmann HJ (2018). "Secondary, AA, Amyloidosis". Rheum Dis Clin North Am. 44 (4): 585–603. doi:10.1016/j.rdc.2018.06.004. PMID 30274625.